More recently, Houshmand et al. [47] developed an innovative strategy based on a liposome loaded with the BCL2 inhibitor venetoclax exploiting begelomab (an anti-CD26 antibody) to selectively target CD26+ CML LSCs. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.